| 摘要: |
| ［摘要］ 低密度脂蛋白胆固醇（LDL-C）升高是动脉粥样硬化的重要危险因素，降低LDL-C可有效减少心脑血管疾病的风险。前蛋白转换酶枯草溶菌素kexin 9型（PCSK9）抑制剂已被证实可以改善心血管疾病的预后。目前临床上已经广泛应用于冠状动脉硬化性心脏病急性期及二级预防的治疗，但其在缺血性脑卒中的应用及对卒中预后的影响报道较少。该文对PCSK9抑制剂在缺血性卒中应用的研究进展作一综述。 |
| 关键词: 前蛋白转换酶枯草溶菌素kexin 9型 缺血性卒中 依洛尤单抗 阿利西尤单抗 |
| DOI：10.3969/j.issn.1674-3806.2021.12.21 |
| 分类号:R 751 |
| 基金项目:国家自然科学基金面上项目（编号：81571145） |
|
| Research progress in the application of PCSK9 inhibitors in ischemic stroke |
|
TIAN Xiao-bing, ZHANG Nan
|
|
Department of Neurology, Tianjin Medical University General Hospital, Tianjin 300052, China
|
| Abstract: |
| ［Abstract］ Elevated level of low-density lipoprotein cholesterol(LDL-C) is an important risk factor for atherosclerosis, and lowering LDL-C level can effectively reduce the risk of cardiovascular and cerebrovascular diseases. Proprotein convertase subtilisin/kexin type 9(PCSK9) inhibitors have been shown to improve the prognosis of patients with cardiovascular disease and are widely used for the treatment of coronary atherosclerotic heart disease at acute phase or its secondary prevention in clinical practice. However, its application in ischemic stroke and its impact on stroke prognosis are rarely reported at present. This paper reviews the research progress in the application of PCSK9 inhibitors in ischemic stroke. |
| Key words: Proprotein convertase subtilisin/kexin type 9(PCSK9) Ischemic stroke Evolocumab Alirocumab |
